Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025RSC AdvancesOpen Access

Design, synthesis, and in silico studies of new benzofuran–pyrazole hybrids as multi-kinase inhibitors with potential antiproliferative activity

View Full Paper
Ask AI
Bookmark
Share

Authors

SESomaia S. Abd El‐KarimYSYasmin M. SyamRAReham M. Abdel‐Kader

Discussion

Loading...

Member takes

Overview

Laboratory synthesis revealed multi-kinase inhibition in novel compounds, suggesting potential therapeutic benefits.

Key Points

  • The compounds exhibited antiproliferative activity against several key kinases, enhancing their therapeutic potential.
  • Specifically, 3d showed effective suppression of B-Raf (V600E), c-Met, Pim-1, and EGFR, making it a promising candidate.
  • A design and synthesis approach was applied to novel benzofuran–pyrazole hybrids, focusing on diverse aromatic systems.
  • This research highlights the importance of multi-kinase inhibitors in cancer therapy, with further studies needed for validation.

Cite This Study

El‐Karim et al. (2025) studied this question.

synapsesocial.com/papers/68de5da783cbc991d0a20e71https://doi.org/10.1039/d5ra00553a
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Design, Synthesis, and Molecular Docking Studies of Triazolylpyridine and Triazolylpyridinylbenzofuran Hybrids as Potential EGFR Inhibitors2025
  2. 2Design, Synthesis, <i>In-Silico</i> Study of Novel Benzofuran Thiazolyl Hydrazones as Anticancer Agents Targeting EGFR Kinase2025
  3. 3Targeted design, synthesis, molecular dynamics, ADME and in –vitro anticancer assessment of oxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids as potential BRAFV600E inhibitors2025
  4. 4Synthesis, biological evaluation, and docking analysis of novel benzimidazole–triazole hybrids as potential anticancer agents2025
  5. 5Examining the 2-aryl-5-nitrobenzofuran-based hydrazones for anti-breast (MCF-7) cancer activity, potential to induce cell cycle arrest and inhibit receptor tyrosine kinases (VEGFR-2 & EGFR)2025 · 11 citations